...
首页> 外文期刊>Gastroenterology Report >Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial
【24h】

Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial

机译:基于随机临床试验的局部晚期直肠癌患者的病理完全反应和肿瘤预测病理完全反应和肿瘤

获取原文
           

摘要

BackgroundPreoperative fluoropyrimidine with radiotherapy was regarded as the standard of care for locally advanced rectal cancer (LARC). The model for predicting pCR in LARC patients was based on standard treatment only. This study aimed to establish a nomogram with pretherapeutic parameters and different neoadjuvant regimens for predicting pathologic complete response (pCR) and tumor downstaging or good response (ypT0-2N0M0) after receiving neoadjuvant treatment in patients with LARC based on a randomized clinical trial.MethodsBetween January 2011 and February 2015, 309 patients with rectal cancer were enrolled from a prospective randomized study (NCT01211210). All pretreatment clinical parameters were collected to build a nomogram for predicting pCR and tumor downstaging. The model was subjected to bootstrap internal validation. The predictive performance of the model was assessed with concordance index (C-index) and calibration plots.ResultsOf the 309 patients, 53 (17.2%) achieved pCR and 132 (42.7%) patients were classified as tumor downstaging with ypT0-2N0M0. Based on the logistic-regression analysis and clinical consideration, tumor length (P?=?0.005), tumor circumferential extent (P?=?0.036), distance from the anal verge (P?=?0.019), and neoadjuvant treatment regimen (P??0.001) showed independent association with pCR following neoadjuvant treatment. The tumor length (P?=?0.015), tumor circumferential extent (P?=?0.001), distance from the anal verge (P?=?0.032), clinical T category (P?=?0.012), and neoadjuvant treatment regimen (P?=?0.001) were significantly associated with good tumor downstaging (ypT0-2N0M0). Nomograms were developed to predict the probability of pCR and tumor downstaging with a C-index of 0.802 (95% confidential interval [CI], 0.736–0.867) and 0.730 (95% CI, 0.672–0.784). Internal validation revealed good performance of the calibration plots.ConclusionsThe nomogram provided individual prediction responses to different preoperative treatment for patients with rectal cancer. This model might help physicians in selecting an optimized treatment, but warrants further external validation.
机译:背景氟丙嘧啶与放射疗法被认为是局部晚期直肠癌(LARC)的护理标准。用于预测LARC患者PCR的模型仅基于标准治疗。本研究旨在建立具有普拉克式参数和不同Neoadjuvant方案的NOMO图案,用于预测基于随机临床试验的LARC患者的Neoadjuvant治疗后预测病理完全反应(PCR)和肿瘤下降或良好反应(YPT0-2N0M0).. 1月份地区) 2011年和2015年2月,来自预期随机研究的309例直肠癌患者(NCT01211210)。收集所有预处理临床参数,以构建用于预测PCR和肿瘤下瓣的NOM图。该模型进行了引导内部验证。通过一致性指数(C-INDEX)和校准曲线评估模型的预测性能。309例患者,53名(17.2%)达到PCR和132名(42.7%)患者被归类为肿瘤下染色,伴有YPT0-2N0M0。基于逻辑回归分析和临床考虑,肿瘤长度(p?= 0.005),肿瘤周向范围(p?= 0.036),距离肛门边缘(p?= 0.019),和新辅助治疗方案( p?<Δ0.001)显示与新辅助治疗后与PCR的独立关联。肿瘤长度(p?= 0.015),肿瘤周向范围(p?= 0.001),距肛门边缘的距离(p?= 0.032),临床T类(p?= 0.012),和新辅助治疗方案(p?= 0.001)与良好的肿瘤下降显着相关(YPT0-2N0M0)。开发了载体以预测PCR和肿瘤下降的概率,其C折射率为0.802(95%机密间隔[CI],0.736-0.867)和0.730(95%CI,0.672-0.784)。内部验证显示了校准图的良好性能.Conclusionsthe NOMAROM为直肠癌患者的不同术前治疗提供了个性化的预测反应。该模型可能有助于医生选择优化的治疗,但保证进一步的外部验证。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号